Aligos Receives FDA Fast Track Designation for Pevifoscorvir Sodium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ALGS?
Source: Newsfilter
- FDA Fast Track Designation: Aligos Therapeutics announced that its drug pevifoscorvir sodium for chronic hepatitis B virus infection has received Fast Track Designation from the FDA, which will expedite its clinical development process to address unmet medical needs.
- Sample Size Increase Recommendation: The independent Data Safety Monitoring Board recommended increasing the sample size of the HBeAg- cohort from 74 to 100 participants to optimize statistical power, indicating that the preliminary results did not meet the predefined futility criteria, enhancing the likelihood of study success.
- Good Tolerability: Among 174 participants, the study drugs demonstrated good tolerability with no clinically concerning laboratory or physical examination abnormalities observed, establishing a solid foundation for further research.
- Data Release Timeline: Aligos expects to release topline data in 2027, with 74 participants currently enrolled in the HBeAg- cohort, and the progress of the study offers new hope for the treatment of chronic hepatitis B.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGS
Wall Street analysts forecast ALGS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.680
Low
20.00
Averages
81.67
High
175.00
Current: 6.680
Low
20.00
Averages
81.67
High
175.00
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
- Deal Details: Aligos has signed a licensing agreement with Xiamen Amoytop, receiving an upfront payment of $25 million and the potential to earn up to $420 million in milestone payments, highlighting the company's prospects in hepatitis B treatment.
- Market Impact: The agreement led to a nearly 20% surge in Aligos shares during pre-market trading, and if sustained, it would mark the largest intraday gain since May 12, 2025, reflecting investor optimism about the company's future.
- Funding Support: Aligos expects that this deal will allow its current cash and investments to support operations into the fourth quarter of 2026, ensuring sufficient funding for future R&D and commercialization efforts.
- Market Opportunity: The drug targets over 90 million chronic hepatitis B patients in Greater China, and the combination with Amoytop's PEGBING® could offer more personalized treatment options, further expanding market share.
See More
Aligos Enters Exclusive Licensing Agreement with Xiamen Amoytop Biotech
- Exclusive Licensing Agreement: Aligos Therapeutics has signed an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus infection across Greater China, marking a strategic move into this significant market.
- Substantial Milestone Payments: Under the terms of the agreement, Aligos will receive an upfront milestone payment of $25 million, with the potential to earn up to $420 million in additional development, regulatory, and commercial milestone payments, highlighting the economic potential of this collaboration.
- Market Responsibility Transfer: Amoytop Biotech will take on the responsibility for development and commercialization in Greater China, while Aligos retains rights to the drug in major markets such as the U.S., Europe, Japan, and South Korea, optimizing resource allocation and market strategy.
- Cost Reduction in Development: This collaboration not only helps Aligos reduce development costs but also extends its financial runway, particularly against the backdrop of a large hepatitis B patient population in Greater China, which presents significant market potential and strategic importance.
See More
Aligos Enters Exclusive License Agreement with Amoytop
- Significant Agreement Value: Aligos has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd., receiving an upfront payment of $25 million and the potential for up to $420 million in clinical, regulatory, and sales milestone payments, indicating substantial financial upside from this deal.
- Market Potential: With over 90 million people living with HBV in Greater China, Amoytop's leadership in the region is expected to facilitate the development and regulatory success of pevifoscorvir sodium, thereby enhancing Aligos's market share in this critical area.
- Retention of Development Rights: Aligos retains development and commercialization rights in the U.S., Europe, South Korea, and Japan while also conducting clinical trials in Greater China, a strategy that will help maintain its competitive edge globally.
- Broad Collaboration Prospects: The partnership between Aligos and Amoytop is poised to not only advance the new drug's development but also potentially offer more personalized treatment options by combining it with Amoytop's PEGBING® therapy, further strengthening its market position in chronic HBV infection treatment.
See More
Aligos Therapeutics Reports Positive Interim Results in HBV Study
- Clinical Trial Progress: Aligos Therapeutics reported that the interim results from its Phase 2 B-SUPREME study of Pevifoscorvir sodium for chronic HBV infection showed good tolerability with no safety signals or viral breakthrough, indicating the drug's potential in HBV treatment.
- DSMB Recommendation: The independent Data Safety Monitoring Board (DSMB) recommended continuing the study and increasing enrollment in the HBeAg-negative cohort to enhance statistical power, suggesting that futility criteria were not met, thereby increasing the likelihood of success at the primary endpoint.
- Market Demand and Drug Potential: Chronic HBV affects over 250 million people globally, with current therapies often only suppressing the virus without eradication, highlighting the urgent need for new therapies; the Fast Track Designation for Pevifoscorvir sodium underscores its potential to meet this need.
- Future Outlook: Enrollment in the HBeAg-negative cohort is expected to complete in the second half of 2026, with topline data anticipated in 2027, while Aligos continues to advance its pipeline in liver and viral diseases, reflecting the company's strategic focus on addressing metabolic dysfunction-associated steatohepatitis and other conditions.
See More
Aligos Receives FDA Fast Track Designation for Pevifoscorvir Sodium
- FDA Fast Track Designation: Aligos Therapeutics announced that its drug pevifoscorvir sodium for chronic hepatitis B virus infection has received Fast Track Designation from the FDA, which will expedite its clinical development process to address unmet medical needs.
- Sample Size Increase Recommendation: The independent Data Safety Monitoring Board recommended increasing the sample size of the HBeAg- cohort from 74 to 100 participants to optimize statistical power, indicating that the preliminary results did not meet the predefined futility criteria, enhancing the likelihood of study success.
- Good Tolerability: Among 174 participants, the study drugs demonstrated good tolerability with no clinically concerning laboratory or physical examination abnormalities observed, establishing a solid foundation for further research.
- Data Release Timeline: Aligos expects to release topline data in 2027, with 74 participants currently enrolled in the HBeAg- cohort, and the progress of the study offers new hope for the treatment of chronic hepatitis B.
See More
Aligos Therapeutics Reports 2025 Financial Progress and Pipeline Advancements
- Reduced Financial Losses: Aligos Therapeutics reported a net loss of $19.9 million for Q4 2025, translating to a basic and diluted net loss per share of $(1.91), a significant improvement from the $82.2 million loss and $(13.08) per share in Q4 2024, indicating progress in cost management and operational efficiency.
- Pipeline Advancements: The company’s drug pipeline includes Pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675, all advancing through clinical and preclinical stages, particularly with Pevifoscorvir sodium in the B-SUPREME study expected to yield key data in 2027, potentially offering new hope for chronic hepatitis B treatment.
- Promising Drug Research: ALG-055009 demonstrated up to 39-40% weight loss in animal studies when combined with weight loss drugs, suggesting it could enhance existing treatment effects, and the company is exploring partnership opportunities for further development, indicating potential market value.
- Strong Financial Position: As of December 31, 2025, Aligos had $77.8 million in cash and equivalents, expected to fund operations into Q3 2026, reflecting financial stability for ongoing R&D and market expansion efforts.
See More
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
- Deal Details: Aligos has signed a licensing agreement with Xiamen Amoytop, receiving an upfront payment of $25 million and the potential to earn up to $420 million in milestone payments, highlighting the company's prospects in hepatitis B treatment.
- Market Impact: The agreement led to a nearly 20% surge in Aligos shares during pre-market trading, and if sustained, it would mark the largest intraday gain since May 12, 2025, reflecting investor optimism about the company's future.
- Funding Support: Aligos expects that this deal will allow its current cash and investments to support operations into the fourth quarter of 2026, ensuring sufficient funding for future R&D and commercialization efforts.
- Market Opportunity: The drug targets over 90 million chronic hepatitis B patients in Greater China, and the combination with Amoytop's PEGBING® could offer more personalized treatment options, further expanding market share.
See More
Aligos Enters Exclusive Licensing Agreement with Xiamen Amoytop Biotech
- Exclusive Licensing Agreement: Aligos Therapeutics has signed an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus infection across Greater China, marking a strategic move into this significant market.
- Substantial Milestone Payments: Under the terms of the agreement, Aligos will receive an upfront milestone payment of $25 million, with the potential to earn up to $420 million in additional development, regulatory, and commercial milestone payments, highlighting the economic potential of this collaboration.
- Market Responsibility Transfer: Amoytop Biotech will take on the responsibility for development and commercialization in Greater China, while Aligos retains rights to the drug in major markets such as the U.S., Europe, Japan, and South Korea, optimizing resource allocation and market strategy.
- Cost Reduction in Development: This collaboration not only helps Aligos reduce development costs but also extends its financial runway, particularly against the backdrop of a large hepatitis B patient population in Greater China, which presents significant market potential and strategic importance.
See More
Aligos Enters Exclusive License Agreement with Amoytop
- Significant Agreement Value: Aligos has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd., receiving an upfront payment of $25 million and the potential for up to $420 million in clinical, regulatory, and sales milestone payments, indicating substantial financial upside from this deal.
- Market Potential: With over 90 million people living with HBV in Greater China, Amoytop's leadership in the region is expected to facilitate the development and regulatory success of pevifoscorvir sodium, thereby enhancing Aligos's market share in this critical area.
- Retention of Development Rights: Aligos retains development and commercialization rights in the U.S., Europe, South Korea, and Japan while also conducting clinical trials in Greater China, a strategy that will help maintain its competitive edge globally.
- Broad Collaboration Prospects: The partnership between Aligos and Amoytop is poised to not only advance the new drug's development but also potentially offer more personalized treatment options by combining it with Amoytop's PEGBING® therapy, further strengthening its market position in chronic HBV infection treatment.
See More
Aligos Therapeutics Reports Positive Interim Results in HBV Study
- Clinical Trial Progress: Aligos Therapeutics reported that the interim results from its Phase 2 B-SUPREME study of Pevifoscorvir sodium for chronic HBV infection showed good tolerability with no safety signals or viral breakthrough, indicating the drug's potential in HBV treatment.
- DSMB Recommendation: The independent Data Safety Monitoring Board (DSMB) recommended continuing the study and increasing enrollment in the HBeAg-negative cohort to enhance statistical power, suggesting that futility criteria were not met, thereby increasing the likelihood of success at the primary endpoint.
- Market Demand and Drug Potential: Chronic HBV affects over 250 million people globally, with current therapies often only suppressing the virus without eradication, highlighting the urgent need for new therapies; the Fast Track Designation for Pevifoscorvir sodium underscores its potential to meet this need.
- Future Outlook: Enrollment in the HBeAg-negative cohort is expected to complete in the second half of 2026, with topline data anticipated in 2027, while Aligos continues to advance its pipeline in liver and viral diseases, reflecting the company's strategic focus on addressing metabolic dysfunction-associated steatohepatitis and other conditions.
See More
Aligos Receives FDA Fast Track Designation for Pevifoscorvir Sodium
- FDA Fast Track Designation: Aligos Therapeutics announced that its drug pevifoscorvir sodium for chronic hepatitis B virus infection has received Fast Track Designation from the FDA, which will expedite its clinical development process to address unmet medical needs.
- Sample Size Increase Recommendation: The independent Data Safety Monitoring Board recommended increasing the sample size of the HBeAg- cohort from 74 to 100 participants to optimize statistical power, indicating that the preliminary results did not meet the predefined futility criteria, enhancing the likelihood of study success.
- Good Tolerability: Among 174 participants, the study drugs demonstrated good tolerability with no clinically concerning laboratory or physical examination abnormalities observed, establishing a solid foundation for further research.
- Data Release Timeline: Aligos expects to release topline data in 2027, with 74 participants currently enrolled in the HBeAg- cohort, and the progress of the study offers new hope for the treatment of chronic hepatitis B.
See More
Aligos Therapeutics Reports 2025 Financial Progress and Pipeline Advancements
- Reduced Financial Losses: Aligos Therapeutics reported a net loss of $19.9 million for Q4 2025, translating to a basic and diluted net loss per share of $(1.91), a significant improvement from the $82.2 million loss and $(13.08) per share in Q4 2024, indicating progress in cost management and operational efficiency.
- Pipeline Advancements: The company’s drug pipeline includes Pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675, all advancing through clinical and preclinical stages, particularly with Pevifoscorvir sodium in the B-SUPREME study expected to yield key data in 2027, potentially offering new hope for chronic hepatitis B treatment.
- Promising Drug Research: ALG-055009 demonstrated up to 39-40% weight loss in animal studies when combined with weight loss drugs, suggesting it could enhance existing treatment effects, and the company is exploring partnership opportunities for further development, indicating potential market value.
- Strong Financial Position: As of December 31, 2025, Aligos had $77.8 million in cash and equivalents, expected to fund operations into Q3 2026, reflecting financial stability for ongoing R&D and market expansion efforts.
See More
